Compare IFBD & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IFBD | LEXX |
|---|---|---|
| Founded | 2001 | 2004 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 8.7M |
| IPO Year | 2020 | 2011 |
| Metric | IFBD | LEXX |
|---|---|---|
| Price | $1.29 | $3.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | ★ 425.9K | 123.0K |
| Earning Date | 05-01-2023 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $705,923.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $601.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 52.05 |
| 52 Week Low | $0.66 | $0.35 |
| 52 Week High | $2.18 | $14.37 |
| Indicator | IFBD | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 70.36 | 36.48 |
| Support Level | $0.87 | $0.57 |
| Resistance Level | $2.18 | $12.89 |
| Average True Range (ATR) | 0.22 | 1.15 |
| MACD | 0.03 | -0.44 |
| Stochastic Oscillator | 35.21 | 7.18 |
Infobird Co Ltd is a software-as-a-service (SaaS) provider of AI-powered customer engagement solutions in China. The Company provides standard and customized customer relationship management cloud-based services, including SaaS and business process outsourcing (BPO) services. It generates revenue from the development and sale of software licenses for customized software, as well as from business integration solution services and digital advertising and marketing campaign services. Digital advertising revenue is generated from developing and executing advertising plans based on customer needs, and the Company generally provides limited warranties for work performed under its business integration solution contracts. The Company generates maximum revenue from its operations in Mainland China.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.